[REVISION HISTORY]

CAR T-cell therapy market and research developments

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-14 05:04 UTC → 2026-08-19 02:02 UTC · added ~~removed~~

The global CAR T-cell therapy market is projected to experience significant growth through the end of the decade. Early projections estimated the market would reach approximately $13.56 billion by 2031, driven by rising cancer incidence and advancements in gene-editing technologies. Subsequent estimates suggest a market value of $6.08 billion by 2030, with a compound annual growth rate of 15.2%. Research into the application of these therapies is expanding beyond hematologic cancers. Clinical investigations are exploring the use of CAR T-cell therapy to treat multiple sclerosis by targeting pathogenic B-cell populations. Additionally, researchers are working to overcome the limitations of the therapy in treating solid tumors. One developed method, known as SHIFTERS, utilizes focused ultrasound to prompt tumor cells to display CD19 markers, potentially allowing CAR-T cells to recognize and attack tumors in the brain, liver, and lungs. In August 2026, CARsgen Therapeutics reported interim results for the first half of the year, noting that the NMPA approved satri-cel in June 2026. The company described satri-cel as the “world’s first and only CAR-T therapy for solid tumors.” As of June 30, 2026, the company held approximately RMB1,400 million in cash and expects to maintain sufficient liquidity through 2030. Further developments include IND approvals from the NMPA for CT0596 and CT1190B in August 2026, alongside the initiation of an investigator-initiated trial for KJ-C2529.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.